Dissolved and financials
CVR: 38613391
DKK -6,100,000
Gross profit
Net result: DKK -8,286,000
No owners listed
CVR · view owners
No management registered
CVR · view management
Dissolved
Ceased 6 October 2026
CVR · view overview
1 employee
CVR · 2026
Director role ended: Johnny Stilou
CVR · 06/10/2026
View the full event history
Scandion Oncology A/S was a Danish company of the type Aktieselskab based in København Ø, founded in 2017. The company has been dissolved on 6 October 2026. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK -6,100,000 and a net result of DKK -8,286,000. Equity in the 2025 report amounted to DKK 0.
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | - | -8.3 mio. | 1.4 mio. | 0 | 1 | |
| 202401/01/2024 – 31/12/2024 | - | - | 18.3 mio. | 8.3 mio. | 4 | |
| 202301/01/2023 – 31/12/2023 | - | - | 34.6 mio. | 31.1 mio. | 7 | |
| 202201/01/2022 – 31/12/2022 | - | - | 89.4 mio. | 70.3 mio. | 14 | |
| 202101/01/2021 – 31/12/2021 | - | -51.7 mio. | 116.2 mio. | 104.5 mio. | - | |
| 202001/01/2020 – 31/12/2020 | 0 | -16.3 mio. | 186.4 mio. | 155.9 mio. | 6 | |
| 201901/01/2019 – 31/12/2019 | 0 | -12.2 mio. | 19.9 mio. | 18.3 mio. | 3 | |
| 201801/01/2018 – 31/12/2018 | 0 | -8.2 mio. | 13.6 mio. | 12.6 mio. | 2 |
Compared to 1.038 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringNo. Scandion Oncology A/S is registered in the Danish CVR register with the status Dissolved and ceased on 6 October 2026.
The CVR number of Scandion Oncology A/S is 38613391.
In 2025, Scandion Oncology A/S reported a gross profit of DKK -6,100,000.
Scandion Oncology A/S had 1 employee in 2026 according to the Danish CVR register.
Scandion Oncology A/S was founded on 2 May 2017.
Scandion Oncology A/S was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (industry code 721000).
As of October 6, 2026, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of Scandion Oncology A/S.
As of October 6, 2026, Johnny Stilou has stepped down as liquidator of Scandion Oncology A/S.
On October 6, 2026, Scandion Oncology A/S exited liquidation.
Scandion Oncology A/S was dissolved on October 6, 2026.
Scandion Oncology A/S has published its annual report for 2025. Gross profit came to DKK -6,100,000, and the net result was DKK -8,286,000.
Scandion Oncology A/S has published its annual report for 2024.
As of March 27, 2025, Per Pfeiffer has left the board of directors of Scandion Oncology A/S.
As of March 27, 2025, Keld Flintholm Jørgensen has left the board of directors of Scandion Oncology A/S.
As of March 27, 2025, Johnny Stilou is registered as liquidator of Scandion Oncology A/S.
As of March 27, 2025, Martin Brygger Møller has stepped down as chairman of Scandion Oncology A/S.
As of March 27, 2025, Alejandra Maria Cristina Bonifacini Mørk has stepped down as vice chairman of Scandion Oncology A/S.
As of March 27, 2025, Francois-Regis Marie Eugene Martelet has stepped down as adm. dir. of Scandion Oncology A/S.
On March 27, 2025, Scandion Oncology A/S entered liquidation.
As of July 1, 2024, Michel Pierre Ducreux has left the board of directors of Scandion Oncology A/S.
Scandion Oncology A/S has published its annual report for 2023.
As of May 6, 2024, Per Pfeiffer has joined the board of directors of Scandion Oncology A/S.
As of May 6, 2024, Michel Pierre Ducreux has joined the board of directors of Scandion Oncology A/S.
As of May 6, 2024, Martine Jannigje van Vugt has left the board of directors of Scandion Oncology A/S.
As of May 6, 2024, Alejandra Maria Cristina Bonifacini Mørk is registered as vice chairman of Scandion Oncology A/S.
As of May 6, 2024, Jørgen Vilhelm Løvenørn Bardenfleth has stepped down as vice chairman of Scandion Oncology A/S.
As of May 5, 2024, Alejandra Maria Cristina Bonifacini Mørk has left the board of directors of Scandion Oncology A/S.
Scandion Oncology A/S has published its annual report for 2022.
As of April 26, 2023, Nils Aage Brünner has left the board of directors of Scandion Oncology A/S.
As of April 26, 2023, Annie Rasmussen has left the board of directors of Scandion Oncology A/S.
As of January 2, 2023, Francois-Regis Marie Eugene Martelet is registered as adm. dir. of Scandion Oncology A/S.
As of January 2, 2023, Johnny Stilou has stepped down as adm. dir. of Scandion Oncology A/S.
As of October 28, 2022, Nils Aage Brünner has joined the board of directors of Scandion Oncology A/S.
As of August 31, 2022, Jens Bo Rode Hansen has left the board of directors of Scandion Oncology A/S.
As of August 31, 2022, Jens Bo Rode Hansen has stepped down as adm. dir. of Scandion Oncology A/S.
As of August 29, 2022, Johnny Stilou is registered as adm. dir. of Scandion Oncology A/S.
As of May 25, 2022, Thomas Feldthus has left the board of directors of Scandion Oncology A/S.
Scandion Oncology A/S has published its annual report for 2021. The net result was DKK -51,705,000.
As of April 27, 2022, Alejandra Maria Cristina Bonifacini Mørk has joined the board of directors of Scandion Oncology A/S.
As of April 27, 2022, Keld Flintholm Jørgensen has joined the board of directors of Scandion Oncology A/S.
As of April 27, 2022, Martine Jannigje van Vugt has joined the board of directors of Scandion Oncology A/S.
As of April 27, 2022, Christian Vinding Thomsen has left the board of directors of Scandion Oncology A/S.
As of April 27, 2022, Karl Arne Krister Borrebaeck has left the board of directors of Scandion Oncology A/S.
As of April 27, 2022, Martin Brygger Møller is registered as chairman of Scandion Oncology A/S.
As of April 27, 2022, Peter Høngård Andersen has stepped down as chairman of Scandion Oncology A/S.
As of April 26, 2022, Martin Brygger Møller has left the board of directors of Scandion Oncology A/S.
Scandion Oncology A/S has published its annual report for 2020. Revenue came to DKK 0, and the net result was DKK -16,269,000.
As of May 26, 2021, Martin Brygger Møller has joined the board of directors of Scandion Oncology A/S.
As of October 1, 2020, Jens Bo Rode Hansen is registered as adm. dir. of Scandion Oncology A/S.
As of October 1, 2020, Nils Aage Brünner has stepped down as adm. dir. of Scandion Oncology A/S.
As of June 23, 2020, Annie Rasmussen has joined the board of directors of Scandion Oncology A/S.
Scandion Oncology A/S has published its annual report for 2019. Revenue came to DKK 0, and the net result was DKK -12,183,591.
As of May 27, 2020, Jens Bo Rode Hansen has joined the board of directors of Scandion Oncology A/S.
As of October 1, 2019, Peter Høngård Andersen is registered as chairman of Scandion Oncology A/S.
As of October 1, 2019, Jørgen Vilhelm Løvenørn Bardenfleth is registered as vice chairman of Scandion Oncology A/S.
As of September 30, 2019, Peter Høngård Andersen has stepped down as vice chairman of Scandion Oncology A/S.
As of September 30, 2019, Jørgen Vilhelm Løvenørn Bardenfleth has stepped down as chairman of Scandion Oncology A/S.
As of May 29, 2019, Thomas Feldthus has joined the board of directors of Scandion Oncology A/S.
As of May 29, 2019, Peter Høngård Andersen is registered as vice chairman of Scandion Oncology A/S.
As of May 28, 2019, Thomas Feldthus has stepped down as vice chairman of Scandion Oncology A/S.
Scandion Oncology A/S has published its annual report for 2018. Revenue came to DKK 0, and the net result was DKK -8,182,558.
As of July 5, 2018, Nils Aage Brünner is registered as adm. dir. of Scandion Oncology A/S.
As of July 5, 2018, Jørgen Vilhelm Løvenørn Bardenfleth is registered as chairman of Scandion Oncology A/S.
As of July 5, 2018, Thomas Feldthus is registered as vice chairman of Scandion Oncology A/S.
As of July 5, 2018, Kim Arvid Nielsen has stepped down as adm. dir. of Scandion Oncology A/S.
As of July 5, 2018, Nils Aage Brünner has stepped down as chairman of Scandion Oncology A/S.
As of July 4, 2018, Jørgen Vilhelm Løvenørn Bardenfleth has left the board of directors of Scandion Oncology A/S.
Scandion Oncology A/S has published its interim report for the period May 2, 2017 – December 31, 2017.
As of June 7, 2017, Christian Vinding Thomsen has joined the board of directors of Scandion Oncology A/S.
As of June 7, 2017, Jørgen Vilhelm Løvenørn Bardenfleth has joined the board of directors of Scandion Oncology A/S.
As of June 7, 2017, Karl Arne Krister Borrebaeck has joined the board of directors of Scandion Oncology A/S.
As of June 7, 2017, Kim Arvid Nielsen has left the board of directors of Scandion Oncology A/S.
As of June 7, 2017, Jan Stenvang has left the board of directors of Scandion Oncology A/S.
As of May 2, 2017, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Scandion Oncology A/S.
As of May 2, 2017, Kim Arvid Nielsen has joined the board of directors of Scandion Oncology A/S.
As of May 2, 2017, Jan Stenvang has joined the board of directors of Scandion Oncology A/S.
As of May 2, 2017, Kim Arvid Nielsen is registered as adm. dir. of Scandion Oncology A/S.
As of May 2, 2017, Nils Aage Brünner is registered as chairman of Scandion Oncology A/S.
Scandion Oncology A/S was founded on May 2, 2017.
Uneven Bits ApS is an independent IT consultancy founded and operated by Klaus Byskov Pedersen. With deep expertise in software architecture and systems design, I help organizations build robust, scalable, and maintainable technical solutions. Whether you need strategic guidance on technology decisions, hands-on architecture work, or help navigating complex technical challenges, I bring focused expertise and a practical approach to every engagement.
Selskabets formål er IT- og kommunikationsvirksomhed samt virksomhed i øvrigt, der efter bestyrelsens skøn står i forbindelse hermed.
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Companies in the same industry and area
CVR 26333210
CVR 41366044
CVR 27701396
CVR 33992890
CVR 43932489
